Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity
The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of a patient.
1. A drug eluting intravascular stent comprising:
(a) a generally cylindrical stent body;
(b) an adherent layer on the stent comprising a composite of polymer and a first active agent selected from a group consisting of resveratrol, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable derivatives thereof, and a second active agent selected from a group consisting of quercetin, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable derivatives thereof, wherein said first and second active agents are dispersed within the polymer,
wherein the concentration of the first active agent based on a surface area of the stent ranges from about 1 to about 5 μg/mm 2 , and the concentration of the second active agent based on the surface area of the stent ranges from about 1 to about 5 μg/mm 2 ,
and wherein the composite includes a plurality of layers.
2. A stent according to claim 1 , wherein the stent body has a metal surface.
3. A stent according to claim 1 , wherein the stent body is micro- or nanoporous.
4. A stent according to claim 1 , wherein the stent body has a polymeric surface.
5. A stent according to claim 1 , wherein the polymer is a bioabsorbable polymer.
6. A stent according to claim 1 , wherein the polymer is a biostable polymer.
7. A stent according to claim 1 , wherein a weight of the first active agent and a weight of the second active agent are in a ratio which is selected from the group consisting of about 1:1, about 1:2, about 2:1, about 1:2.5, about 2.5:1, about 1:4, about 4:1, about 1:5, about 5:1, about 1:10, about 10:1, about 1:20, about 20:1, about 1:25, about 25:1, about 1:50, about 50:1, about 1:100, about 100:1, about 1:200, about 200:1, about 1:250, about 250:1, about 1:500, and about 500:1.
8. The stent according to claim 1 , wherein a weight of the first active agent and a weight of the second active agent are in a ratio which is selected from a group consisting of about 1:5, about 1:2, and about 1:1.
9. The stent of claim 1 wherein the coating is a polymer selected from a group consisting of polystyrene-polyisobutylene block copolymers, polyethylene terephthalate, poly(lactide), poly(lactide-co-glycolide), poly(caprolactone), poly(lactide-co-caprolactone), poly-(hydroxybutyrate/hydroxyvalerate) copolymer, poly(vinylpyrrolidone), polytetrafluoroethylene, poly(2-hydroxyethylmethacrylate), poly(n-butyl methacrylate), poly(ethylene-co-vinyl acetate), poly(vinylidene fluoride-co-hexafluoropropene), poly(etherurethane urea), silicones, acrylics, epoxides, polyesters, polyurethanes, desaminotyrosine polyarylate, parylenes [polyxylylenes], polyphosphazene polymers, fluoropolymers, polyamides, isoolefin homopolymers and copolymers, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, methacrylate homopolymers and copolymers, polyethers, polyesters, polycarbonates and copolymers, polyethylene oxides, poly(ethylene glycol) and derivatives, carbo-films, self-assembling polymer films and liposomes cellulosics, chondroitin-sulfate, gelatin, amino acid-based polymers, fibrin, chitin, extracellular matrix proteins, heparinized coatings, phospholipid liposomes and self-assembled arrays, poly-lactides and mixtures thereof.
10. A stent according to claim 1 wherein
a first weight comprises a combined weight of the first and second active agents;
a second weight comprises a weight of the polymer; and
the first weight and the second weight are in a ratio selected from a group consisting of about 1:1, about 1:2, about 2:1, about 1:2.5, about 2.5:1, about 1:4, about 4:1, about 1:5, about 5:1, about 1:10, about 10:1, about 1:20, about 20:1, about 1:25, about 25:1, about 1:50, about 50:1, about 1:100, about 100:1, about 1:200, about 200:1, about 1:250, about 250:1, about 1:500, and about 500:1.
11. The stent according to claim 10 , wherein the ratio is varied in some of the layers.
12. The stent of claim 1 wherein at least one of the active agents are selected from agents which treat or prevent atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition within a body of a patient.
13. The stent of claim 1 , wherein each of the active agents have release profiles selected from a group consisting of a same release profile and a different release profile.
14. The stent of claim 1 , wherein the active agents have a release profile which is selected from a group consisting of a rapid release profile and a delayed release profile.
15. The stent of claim 1 , wherein a rapid profile coating releases one of the active agents substantially within one to a few hours.
16. The stent of claim 1 , wherein a delayed profile coating releases one of the active agents over a period of at least one month, at least two months, at least six months, or at least one year.